Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectiou... ( SOUTH SAN FRANCISCO Calif. Dec. 6...)

Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea

Date:12/6/2007

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL), which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners, is pleased to announce that its licensee, Glenmark Pharmaceuticals Limited, ("Glenmark" - BSE - id 532296) has initiated a Phase 2 clinical trial for crofelemer for the indication of acute infectious diarrhea at two sites in India. This placebo-controlled crofelemer trial is expected to conclude in six months.

Glenmark licensed crofelemer for the indications of acute infectious diarrhea, chronic diarrhea in persons living with HIV/AIDS and pediatric diarrhea in over 140 emerging economies and developing countries. Once these indications are approved in Glenmark's territories, Glenmark will pay ascending royalties to Napo on sales of crofelemer for these indications.

Glenmark is the manufacturer of crofelemer API (active pharmaceutical ingredient) for Napo's current Phase 3 trial for crofelemer for chronic diarrhea in persons living with HIV/AIDS, which is being conducted at sites in the United States under a special protocol assessment agreement with the FDA.

"We are delighted that Glenmark has moved forward with this trial," said Lisa A. Conte, CEO of Napo. "Including Glenmark's current trial, we are expecting clinical results from four trials of crofelemer around the end of Q1 2008, including the interim results from the Phase 3 CRO-HIV trial and look forward to filing a NDA for this fast tracked indication in Q3 2008."

For more information please contact:

Napo Pharmaceuticals, Inc.

Lisa Conte, Chief Executive Officer

(001) + 650 616 1902

Charles Thompson, Chief Financial Officer

(001) + 650 616 1903

Buchanan Communications

(44) + 020 7466 5000

Tim Anderson, Mary-Jane Johnson

About Napo Pharmaceuticals, Inc.

Napo
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Lilly and Glenmark Pharmaceuticals Announce License Agreement
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes

Post Your Comments:

Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectiou...( SOUTH SAN FRANCISCO Calif. Dec. 6...),Health